Nektar Therapeutics (NKTR)

[surf1944]

1:08AM Nektar Therapeutics reports positive results from Phase 2 clinical study of NKTR-102 in metastatic breast cancer (NKTR) 5.06 : Co announces positive results from the co's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer. NKTR-102 achieved a confirmed objective response rate by RECIST of 29 percent. In addition, 71 percent of patients in the study had no tumor progression, defined as complete response, partial response and stable disease, as measured by RECIST criteria. NKTR-102 also demonstrated a high clinical benefit rate of 46% (30 of 66). Six patients experienced 100% resolution of all target lesions, with two complete RECIST responses and four near-complete responses. Objective tumor responses were maintained in heavily pretreated and poor prognosis subsets, including patients previously treated with anthracycline/taxane/capecitabine, patients with metastatic triple-negative breast cancer and patients with visceral disease. Eighty-nine percent (62/70) of patients in the study received a prior anthracycline/taxane with or without capecitabine. A total of 66 of the 70 patients treated with single-agent NKTR-102 in the Phase 2 clinical study were assessable for the primary endpoint of objective tumor response rate.